Clinical trial
RAV12 in Treating Patients With Metastatic or Recurrent Adenocarcinoma
NCT00101972 · MacroGenics, Industry · Completed
Key facts
| NCT number | NCT00101972 |
|---|---|
| Title | RAV12 in Treating Patients With Metastatic or Recurrent Adenocarcinoma |
| Official title | A Phase I, Multi-Dose Study of RAV12 (ANTI-RAAG12 MAB) in Patients With Metastatic or Recurrent Adenocarcinoma |
| Lead sponsor | MacroGenics, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Cancer |
| Intervention type | Biological |
| Interventions | monoclonal antibody RAV12 |
| Enrollment | 53 |
| Start date | Dec 1, 2004 |
| Primary completion | May 1, 2008 |
| Completion | May 1, 2008 |
| First posted | Jan 19, 2005 |
| Last update posted | Feb 22, 2022 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: